Evaluation of the Absolute Bioavailability of Pegylated Interferon Alfa-2a After Subcutaneous Administration to Healthy Male Volunteers: An Open-Label, Randomized, Parallel-Group Study

Trial Profile

Evaluation of the Absolute Bioavailability of Pegylated Interferon Alfa-2a After Subcutaneous Administration to Healthy Male Volunteers: An Open-Label, Randomized, Parallel-Group Study

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2012

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Peginterferon alfa-2a (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 29 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top